Status:

COMPLETED

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

Lead Sponsor:

Ironwood Pharmaceuticals, Inc.

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18-65 years

Phase:

PHASE2

Brief Summary

* The primary objective of this trial is to compare the dose-ranging pharmacodynamic effects of orally administered placebo, and 100 and 1000 ug qd of MD-1100 Acetate on gastrointestinal transit in pa...

Detailed Description

Using a double-blind, randomized, placebo-controlled, parallel group study design, the effects of placebo and two different doses of orally administered MD-1100 Acetate on gastric emptying, small bowe...

Eligibility Criteria

Inclusion

  • Patient agrees to use a medically accepted, double-barrier form of contraception (e.g., IUD and condom) during participation;
  • No evidence of pelvic floor dysfunction and the completion of a negative digital rectal exam prior to the first dose of study medication;
  • Absence of an evacuation disorder as defined per protocol;
  • Patients must meet ROME II Criteria for C-IBS;
  • The patient's Baseline Colonic Transit Test must show a geometric center (GC) ≤ 2.65 at 24 hours, or ≤ 3.0 at 24 hours and ≤ 3.9 at 48 hours.

Exclusion

  • History of clinically-significant manifestations of any major system organ class;
  • History of inflammatory bowel disease or gastric ulcers;
  • Significant GI surgery within 6 months;
  • Clinically-significant prolonged diarrhea within 60 days;
  • Special dietary habit and/or an intense physical workout program within 4 weeks;
  • Certain drug hypersensitivities
  • History of alcoholism or drug addiction within 12 months;
  • Receipt of an investigational drug during the study or within 30 days;
  • Use of any prescription medication or OTC, non-prescription medications disallowed by the protocol within 7 days.

Key Trial Info

Start Date :

January 1 2006

Trial Type :

INTERVENTIONAL

End Date :

September 1 2006

Estimated Enrollment :

36 Patients enrolled

Trial Details

Trial ID

NCT00258193

Start Date

January 1 2006

End Date

September 1 2006

Last Update

October 20 2006

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic Foundation

Rochester, Minnesota, United States